Tasipimidine Formulations And Use Thereof

Abstract: The present disclosure relates to a pharmaceutical composition in the form of an orally deliverable liquid composition comprising tasipimidine, or a pharmaceutically acceptable salt thereof, as an active ingredient and to the use thereof in the treatment and prevention of a disorder, condition or disease where an alpha2A agonist is indicated to be useful, for example, for use as a sedative or analgesic agent, and for use in the treatment of anxiety or agitation. The composition is stable at the pH range from about 2.0 to about 5.0.

Patent Information

Application #

Filing Date

16 October 2023

Publication Number

36/2024

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

ORION CORPORATION

Orionintie 1 02200 Espoo

Inventors

1. KUJALA, Johanna

c/o ORION CORPORATION P.O.Box 65 02101 Espoo

2. LEHTISALO, Jenni

c/o ORION CORPORATION P.O.Box 65 02101 Espoo

3. SALMIA, Jukka

c/o ORION CORPORATION P.O.Box 65 02101 Espoo

4. SINERVO, Kai

c/o ORION CORPORATION P.O.Box 65 02101 Espoo

Specification

Documents

Application Documents

#	Name	Date
1	202317069526-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [16-10-2023(online)].pdf	2023-10-16
2	202317069526-STATEMENT OF UNDERTAKING (FORM 3) [16-10-2023(online)].pdf	2023-10-16
3	202317069526-FORM 1 [16-10-2023(online)].pdf	2023-10-16
4	202317069526-DECLARATION OF INVENTORSHIP (FORM 5) [16-10-2023(online)].pdf	2023-10-16
5	202317069526-COMPLETE SPECIFICATION [16-10-2023(online)].pdf	2023-10-16
6	202317069526-FORM-26 [27-12-2023(online)].pdf	2023-12-27
7	202317069526-Proof of Right [18-03-2024(online)].pdf	2024-03-18
8	202317069526-FORM 3 [18-03-2024(online)].pdf	2024-03-18
9	202317069526-FORM 18 [24-12-2024(online)].pdf	2024-12-24